<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ESTRIOL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ESTRIOL</h1>


      <nav>
        <ul class="nav nav-list">

          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">




      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Not known to be harmful.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin- Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Manufacturer advises caution in renal disease. Evidence for caution is unsatisfactory and many women with these conditions may stand to benefit from HRT.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Active arterial thromboembolic disease (e.g. angina or myocardial infarction)</li>
            <li>active thrombophlebitis</li>
            <li>Dubin-Johnson syndrome (or monitor closely)</li>
            <li>history of breast cancer</li>
            <li>history of recurrent venous thromboembolism (unless already on anticoagulant treatment)</li>
            <li>oestrogen-dependent cancer</li>
            <li>recent arterial thromboembolic disease (e.g. angina or myocardial infarction)</li>
            <li>Rotor syndrome (or monitor closely)</li>
            <li>thrombophilic disorder</li>
            <li>undiagnosed vaginal bleeding</li>
            <li>untreated endometrial hyperplasia</li>
            <li>venous thromboembolism</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Abdominal bloating, abdominal cramps, altered blood lipids (may lead to pancreatitis, rashes and chloasma), breast enlargement, breast tenderness, changes in libido, cholestatic jaundice, contact lenses may irritate, depression, dizziness, fluid retention, glucose intolerance, headache, leg cramps, migraine, mood changes, nausea, premenstrual-like syndrome, sodium retention, vaginal candidiasis, vomiting, weight changes,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>notKnown:</strong> local irritation,
              </p>
        
            <section class="advice">
                <h3>Leg Cramps</h3>
              <p>Venous thrombosis should be ruled out.</p>
            </section>
            <section class="advice">
                <h3>Withdrawal Bleeding</h3>
              <p>Cyclical HRT (where a progestogen is taken for 12&#8211;14 days of each 28-day oestrogen treatment cycle) usually results in <i>regular withdrawal bleeding</i> towards the end of the progestogen. The aim of continuous combined HRT (where a combination of oestrogen and progestogen is taken, usually in a single tablet, throughout each 28-day treatment cycle) is to avoid bleeding, but <i>irregular bleeding</i> may occur during the early treatment stages (if it continues endometrial abnormality should be excluded and consideration given to cyclical HRT instead).</p>
            </section>
        
      </section>





      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            <xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref>
          </li>
          <li>
            diabetes (increased risk of heart disease)
          </li>
          <li>
            factors predisposing to thromboembolism
          </li>
          <li>
            history of breast nodules&#8212;closely monitor breast status (risk of breast cancer)
          </li>
          <li>
            history of endometrial hyperplasia
          </li>
          <li>
            history of fibrocystic disease&#8212;closely monitor breast status (risk of breast cancer)
          </li>
          <li>
            hypophyseal tumours
          </li>
          <li>
            increased risk of gall-bladder disease
          </li>
          <li>
            migraine (or migraine-like headaches)
          </li>
          <li>
            presence of antiphospholipid antibodies (increased risk of thrombotic events)
          </li>
          <li>
            prolonged exposure to unopposed oestrogens may increase risk of developing endometrial cancer
          </li>
          <li>
            risk factors for oestrogen-dependent tumours (e.g. breast cancer in first-degree relative)
          </li>
          <li>
            symptoms of endometriosis may be exacerbated
          </li>
          <li>
            uterine fibroids may increase in size
          </li>
        </ul>
        <ul>
          <li>
              <strong>With vaginal use:</strong>
            interrupt treatment periodically to assess need for continued treatment
          </li>
        </ul>
        <ul>
          <li>
            <p>It is estimated that using <i>all</i> types of HRT increases the risk of breast cancer within 1&#8211;2 years of initiating treatment. The increased risk is related to the duration of HRT use (but not to the age at which HRT is started) and this excess risk disappears within 5 years of stopping.</p><p>Radiological detection of breast cancer can be made more difficult as mammographic density can increase with HRT use.</p>
          </li>
          <li>
            <p>The increased risk of endometrial cancer depends on the dose and duration of oestrogen-only HRT.</p><p>In women with a uterus, the addition of a progestogen cyclically (for at least 10 days per 28-day cycle) reduces the additional risk of endometrial cancer; this additional risk is eliminated if a progestogen is given continuously. However, this should be weighed against the increased risk of breast cancer.</p>
          </li>
          <li>
            <p>Long-term use of combined HRT or oestrogen-only HRT is associated with a small increased risk of ovarian cancer. This excess risk disappears within a few years of stopping.</p>
          </li>
          <li>
            <p>Women using combined or oestrogen-only HRT are at an increased risk of deep vein thrombosis and of pulmonary embolism especially in the first year of use.</p><p>In <i>women who have predisposing factors</i> (such as a personal or family history of deep vein thrombosis or pulmonary embolism, severe varicose veins, obesity, trauma, or prolonged bed-rest) it is prudent to review the need for HRT, as in some cases the risks of HRT may exceed the benefits.</p><p>
        <i>Travel</i> involving prolonged immobility further increases the risk of deep vein thrombosis.</p>
          </li>
          <li>
            <p>Risk of stroke increases with age, therefore older women have a greater absolute risk of stroke. Combined HRT or oestrogen-only HRT slightly increases the risk of stroke.</p>
          </li>
          <li>
            <p>HRT does not prevent coronary heart disease and should not be prescribed for this purpose. There is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause. Although very little information is available on the risk of coronary heart disease in younger women who start HRT close to the menopause, studies suggest a lower relative risk compared with older women.</p>
          </li>
          <li>
            <p>The product literature advises caution in other conditions including hypertension, renal disease, asthma, epilepsy, sickle-cell disease, melanoma, otosclerosis, multiple sclerosis, and systemic lupus erythematosus (but care required if antiphospholipid antibodies present). Evidence for caution in these conditions is unsatisfactory and many women with these conditions may stand to benefit from HRT.</p>
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Intravaginal cream may damage latex condoms and diaphragms.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Closely monitor breast status if history of breast nodules or fibrocystic disease (risk of breast cancer).</p>
            </section>
            <section class="patientParameters">
              <p>The endometrial safety of long-term or repeated use of topical vaginal oestrogens is uncertain; treatment should be reviewed at least annually, with special consideration given to any symptoms of endometrial hyperplasia or carcinoma.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ESTRIOL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP94802"><a href="../medicinalForm/PHP94802.html" data-target="#PHP94802" data-action="load">Cream</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
